Share

Patients in this study are using the eye drop four times a day, which maintains the amount of drug throughout 24 hours. OT-551 is antioxidant, anti-inflammation and anti angiogenic. It protects the retina from oxidative damage from sunlight, reduces swelling and works against the growth of blood vessels.

Called “OMEGA”, the study compares safety and efficacy of OT-551 with a placebo eye drop. Over two years, researchers seek to learn if the drop does reduce progression of area of GA. An interim report on the first 12 months of data will be released in the Spring of 2009.

This study is NOT recruiting any new patients. If the Phase II trial gives some promising results, a Phase III study would open to many more people with dry AMD and geographic atrophy. When that study opens, we will announce it so you could participate if you are eligible.